Merck to test single-dose regimen of HPV vaccine Gardasil 9

The company said it plans to conduct two separate trials testing Gardasil 9 in men and women 16-26 years old to examine whether a single dose of the vaccine provides comparable long-term protection when compared with the approved three-dose regimen. The large, multi-year trials are expected to start enrollment in the fourth quarter of 2024, according to Merck. The drugmaker also plans to begin human trials for an experimental HPV vaccine in the fourth quarter that is designed to offer broader protection by targeting multiple HPV types.